MDMA-assisted Therapy

Veterans Deserve Access To Life-Changing Psychedelics Therapy: A Vital Solution For PTSD And Healing
FDA Public Meeting Reveals Federal Support For Psychedelics In PTSD Care
Veterans Affairs Eyes Funding For New MDMA-PTSD Trial After FDA Setback
FDA Public Meeting Reveals Federal Support For Psychedelics In PTSD Care
Veterans Affairs Eyes Funding For New MDMA-PTSD Trial After FDA Setback
PharmAla Biotech To Supply LaNeo MDMA For Mt. Sinai Clinical Trial
PharmAla Biotech To Supply University Of Texas, San Antonio For Clinical Trial

MDMA-assisted Therapy Recent News

Multidisciplinary Association For Psychedelic Studies Eyes State-Level Legalization After FDA Denial Of MDMA Therapy
MAPS shifts focus to state-level MDMA therapy legalization after FDA denial, advocating for ballot measures in states like Colorado, Oregon, and Massachusetts.
Drug Science Research Group And London College Team Up To Advance MDMA-Assisted Therapy
Drug Science and UCL collaborate to refine MDMA-assisted therapy, addressing FDA concerns and enhancing psychotherapeutic practices for improved treatment outcomes.
Multidisciplinary Association For Psychedelic Studies Funds MDMA-Assisted Therapy Trial For PTSD
MAPS funds a $200K pilot study at Emory University exploring the synergy between MDMA-assisted therapy and Massed Exposure Therapy for PTSD.
Lykos Therapeutics Strategic Reorganization Following FDA's Decision Rejecting MDMA For PTSD Treatment
Lykos Therapeutics announces a strategic reorganization to address the FDA's decision on midomafetamine capsules for PTSD, appointing Dr. David Hough as senior medical advisor and reducing its workforce by 75%.
MDMA Therapy Papers Retracted Amid Ethical Concerns At Lykos Study Site
Psychopharmacology retracts MDMA therapy papers due to ethical misconduct, while Lykos Therapeutics faces FDA rejection for PTSD treatment application.
Five Out Of Six Studies On MDMA Show Positive Results, Yet FDA Approval Still Faces Hurdles
A new review finds MDMA therapy for PTSD promising but calls for more research before widespread adoption. Lawmakers urge FDA to reconsider its decision.
Veterans Groups Urge FDA To Approve MDMA-Assisted Therapy For PTSD As August Decision Looms
Army boots near White House highlight veterans' suicide crisis, as advocates urge the FDA to approve MDMA-assisted therapy for PTSD.
Two Top Biotechs Forge MDMA Supply Deals For An Expanding Research Field
Atai Life Sciences Shows Positive Results In Phase 1 Clinical Study For PTSD Treatment
Biopharma company Atai Life Sciences (NASDAQ: ATAI) shared positive results from a Phase 1 clinical study on MDMA R-enantiomer, EMP-01, under development for the potential treatment of PTSD.
Could MDMA Revolutionize PTSD Treatment? In Historic Move, FDA Considers New Drug Application
The for-profit arm of the legendary Multidisciplinary Association for Psychedelic Studies, MAPS Public Benefit Corporation (MAPS PBC), has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for MDMA (midomafetamine capsules) paired with psychological interventio
Canadian Practitioners Can Now Enroll In MDMA-Assisted Psychotherapy Training Program
Canadian not-for-profit organization TheraPsil has received board approval to launch its training program on MDMA-assisted psychotherapy for trauma survivors.
Psychedelics Researchers & Industry Leaders Weigh In On Groundbreaking PTSD Treatment News
The long-awaited psychedelic-assisted treatment alternative for Post-Traumatic Stress Disorder (PTSD) is moving closer to federal approval. 
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next
MAPS Public Benefit Corporation (MAPS PBC), the nonprofit’s clinical-stage private arm, published new data from its second multi-site, ethno-racially diverse Phase 3 clinical study of MDMA-assisted therapy
Fluence Inks Deal To Bring Brazil's Psychedelic Therapy Training Scene To New Heights
Psychedelic therapy training company Fluence is partnering with Brazil-based nonprofit research organization Phaneros Institute.
MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University
Numinus Wellness (OTCMKTS: NUMIF) with support from the Multidisciplinary Association for Psychedelic Studies (MAPS) will utilize Optimi Health’s (OTCMKTS: OPTHF) Good Manufacturing Practice (GMP)-compliant MDMA to conduct a therapist-experiential training program. 
Numinus Partners With MAPS To Conduct Phase 1 MDMA Assisted Therapy Investigational Study
In a prelude to what is hoped will be regulatory approval of MDMA-assisted therapy in the U.S. and Canada, Numinus Wellness Inc. (OTC: NUMIF) has taken steps to get out in front of the curve.
Promising Milestone: FDA Approves California-Based Trial Assessing MDMA For Schizophrenia
The FDA has approved a clinical trial that will assess PharmAla Biotech Holdings' (OTC: PMBHF) proprietary LaNeo Investigational Medical Product (IMP) 40mg MDMA capsules for the treatment of schizophrenia. This is the first time these capsules will be tried on humans in the U.S
Creso Pharma's LOI For Import Of Swiss MDMA And Psilocybin Therapeutics To Australia
Australia-based cannabis and psychedelics company Creso Pharma Ltd. (OTCMKTS: COPHF) inked a Letter of Intent (LOI) with Swiss pharmacy Apotheke Dr.
EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps
In the current psychedelics landscape, one of the most important topics is compound legality.  While it's possible that MDMA-assisted therapy will eventually be federally approved in the U.S., what should investors consider when looking at a prospective business?
Revolutionizing Psychedelics: 2 Industry Leaders Collaborate To Offer Clinical-Grade MDMA Capsules
MDXX-class molecules producer PharmAla Biotech Holdings Inc.
MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update
Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to deliver MDMA toward IND-enabling studies, supported by an exclusive supply deal with PharmaAla Biotech Holdings Inc.
MDMA News: Exclusive Supply Deal With Awakn Life Sciences & Canadian Company Expands Psychedelics Production
PharmAla To Be Exclusive MDMA Supply Partner To Awakn Life Sciences Effective immediately, MDXX class molecules producer PharmAla Biotech Holdings Inc. will become the exclusive MDMA supplier to Awakn Life Sciences (OTCMKTS: AWKNF).
Australia's Psychedelics Therapy Provides Hope For Treatment-Resistant Mental Health Conditions
As of July 1, psilocybin and MDMA (and related substances to both) can now be prescribed by authorized psychiatrists in Australia, which has become the

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved